Annals of internal medicine
-
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease in the United States. It is characterized by steatosis in the liver and is potentially reversible. Risk factors include obesity, type 2 mellitus, and other metabolic disorders. ⋯ Diet, exercise, and weight loss are the cornerstones of management. Although only 1 medication has been approved for treatment of MASH, other pharmacotherapies and surgeries that aid weight loss and optimize metabolic risk factors can be used. Early diagnosis and intervention are important to prevent progression to cirrhosis and its complications, including cancer.
-
Randomized Controlled Trial
In HF with mildly reduced or preserved ejection fraction, finerenone reduced worsening HF or CV death at 32 mo.
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].
-
There is a paucity of data on treatment of osteoporosis in patients with advanced chronic kidney disease (CKD). ⋯ U.S. Food and Drug Administration.
-
Randomized Controlled Trial Multicenter Study
In insulin-naive T2D, weekly efsitora was noninferior to daily degludec for reducing HbA1c at 52 wk.
GIM/FP/GP: [Formula: see text] Endocrinology: [Formula: see text].